Trial
NCT02477800
221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Biogen
Collaborators
—
Condition
Alzheimer's Disease
Intervention
Aducanumab (BIIB037)
Why stopped
Study was discontinued based on futility analysis done and not based on safety concerns. Follow-up visits and closing out study activities are completed
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-09-02